Treatment of antiphospholipid syndrome beyond anticoagulation.
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
16
02
2018
revised:
02
03
2018
accepted:
02
03
2018
pubmed:
7
3
2018
medline:
12
5
2020
entrez:
7
3
2018
Statut:
ppublish
Résumé
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). At the present time, treatment is primarily focused on anticoagulation. However, there is increasing awareness of the mechanisms involved in APS pathogenesis, which has led to the trial of novel therapies targeting those mechanisms. Following a brief review of the etiopathogenesis of and current management strategies in APS, this paper focuses on the evidence for these potential, targeted APS treatments, e.g., hydroxychloroquine, statins, rituximab, belimumab, eculizumab, defibrotide, sirolimus, and peptide therapy.
Identifiants
pubmed: 29510235
pii: S1521-6616(18)30119-0
doi: 10.1016/j.clim.2018.03.001
pii:
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Anticoagulants
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-62Informations de copyright
Copyright © 2018. Published by Elsevier Inc.